Evidence supporting the use of: Alpha lipoic acid
For the health condition: Nerve Damage

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Alpha lipoic acid (ALA) is considered to have scientific support for its use in treating certain types of nerve damage, particularly diabetic neuropathy. Several randomized controlled trials and meta-analyses have investigated the efficacy of ALA in reducing symptoms such as pain, burning, and numbness in patients with diabetic peripheral neuropathy. The proposed mechanisms include its antioxidant properties, which may help to counteract oxidative stress—a key factor in nerve damage associated with diabetes.

A notable meta-analysis published in Diabetes Care (2006) reviewed four trials involving over 1,200 participants and found that intravenous ALA (600 mg/day for three weeks) significantly improved neuropathic symptoms compared to placebo. Oral ALA has also been studied, with some research suggesting modest benefits, though results are less consistent than with intravenous use.

Despite these findings, ALA is not universally recommended as a first-line therapy. Guidelines such as those from the American Academy of Neurology acknowledge the modest benefit but also point out limitations in the evidence, such as short study durations and variability in outcome measures. Importantly, ALA is generally well tolerated, with only mild side effects reported in most studies.

In summary, alpha lipoic acid has a moderate level of scientific evidence supporting its use in diabetic neuropathy and possibly other forms of nerve damage, primarily due to its antioxidant effects, though more high-quality, long-term research is needed.

More about alpha lipoic acid
More about Nerve Damage